My NCBISign In
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
Andrea Molckovsky, Lillian L Siu
J Hematol Oncol. 2008; 1: 20. Published online 2008 October 29. doi: 10.1186/1756-8722-1-20
PMCID:
PMC2647552
Abstract Full Text PDF–259K

Is Cited by the Following 20 Articles in this Archive:

The mTOR Signalling Pathway in Human Cancer
Helena Pópulo, José Manuel Lopes, Paula Soares
Int J Mol Sci. 2012; 13(2): 1886–1918. Published online 2012 February 10. doi: 10.3390/ijms13021886
PMCID:
PMC3291999
Abstract Full Text PDF–677K
Telomerase-Independent Paths to Immortality in Predictable Cancer Subtypes
Stephen T Durant
J Cancer. 2012; 3: 67–82. Published online 2012 January 31. doi: 10.7150/jca.3965
PMCID:
PMC3273709
Abstract Full Text PDF–1.0M
Current development of the second generation of mTOR inhibitors as anticancer agents
Hong-Yu Zhou, Shi-Le Huang
Chin J Cancer. Author manuscript; available in PMC 2013 January 5.
Published in final edited form as: Chin J Cancer. 2012 January 5; 31(1): 8–18. Published online 2011 November 4. doi: 10.5732/cjc.011.10281
PMCID:
PMC3249493
Free in PMC on 2013/01/05
Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer
Diego Serrano, Anne-Marie Bleau, Ignacio Fernandez-Garcia, Tamara Fernandez-Marcelo, Pilar Iniesta, Carlos Ortiz-de-Solorzano, Alfonso Calvo
Mol Cancer. 2011; 10: 96. Published online 2011 August 9. doi: 10.1186/1476-4598-10-96
PMCID:
PMC3199900
Abstract Full Text PDF–6.1M Supplementary Material
Emerging antibody combinations in oncology
Stephen J Demarest, Kandasamy Hariharan, Jianying Dong
MAbs. 2011 Jul-Aug; 3(4): 338–351. Published online 2011 July 1. doi: 10.4161/mabs.3.4.16615
PMCID:
PMC3218531
Free in PMC on 2012/07/01
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
S.J Shuttleworth, F.A Silva, A.R.L Cecil, C.D Tomassi, T.J Hill, F.I Raynaud, P.A Clarke, P Workman
Curr Med Chem. 2011 June; 18(18): 2686–2714. doi: 10.2174/092986711796011229
PMCID:
PMC3228236
Abstract Full Text PDF–762K
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell, Linda S. Steelman, Jacquelyn M. Long, Ruth C. Kempf, Stephen L. Abrams, Richard A. Franklin, Jörg Bäsecke, Franca Stivala, Marco Donia, Paolo Fagone, Graziella Malaponte, Maria C. Mazzarino, Ferdinando Nicoletti, Massimo Libra, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Giuseppe Montalto, Melchiorre Cervello, Piotr Laidler, Michele Milella, Agostino Tafuri, Antonio Bonati, Camilla Evangelisti, Lucio Cocco, Alberto M. Martelli, James A. McCubrey
Oncotarget. 2011 March; 2(3): 135–164. Published online 2011 March 11.
PMCID:
PMC3260807
Abstract Full Text PDF–1.3M
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
Yan-Jie Zhang, Yanwen Duan, X. F. Steven Zheng
Drug Discov Today. Author manuscript; available in PMC 2012 April 1.
Published in final edited form as: Drug Discov Today. 2011 April; 16(7-8): 325–331. Published online 2011 February 17. doi: 10.1016/j.drudis.2011.02.008
PMCID:
PMC3073023
Abstract Full Text PDF–549K
Targeting Focal Adhesion Kinase in Neuroblastoma
Lauren Gillory, Elizabeth A. Beierle
Anticancer Agents Med Chem. Author manuscript; available in PMC 2011 December 1.
Published in final edited form as: Anticancer Agents Med Chem. 2010 December; 10(10): 714–721.
PMCID:
PMC3225183
Abstract Full Text PDF–638K
PI3Kα Inhibitors That Inhibit Metastasis
Oleg Schmidt-Kittler, Jiuxiang Zhu, Jian Yang, Guosheng Liu, William Hendricks, Christoph Lengauer, Sandra B. Gabelli, Kenneth W. Kinzler, Bert Vogelstein, David L. Huso, Shibin Zhou
Oncotarget. 2010 September; 1(5): 339–348. Published online 2010 September 11.
PMCID:
PMC3004370
Abstract Full Text PDF–1.0M Supplementary Material
The complexes of mammalian target of rapamycin
Hongyu Zhou, Shile Huang
Curr Protein Pept Sci. Author manuscript; available in PMC 2011 September 1.
Published in final edited form as: Curr Protein Pept Sci. 2010 September 1; 11(6): 409–424.
PMCID:
PMC2928868
Abstract Full Text PDF–439K
Frequent Deregulations in the Hedgehog Signaling Network and Cross-Talks with the Epidermal Growth Factor Receptor Pathway Involved in Cancer Progression and Targeted Therapies
Murielle Mimeault, Surinder K. Batra
Pharmacol Rev. 2010 September; 62(3): 497–524. doi: 10.1124/pr.109.002329
PMCID:
PMC2964899
Abstract Full Text PDF–2.3M
Updates of mTOR inhibitors
Hongyu Zhou, Yan Luo, Shile Huang
Anticancer Agents Med Chem. Author manuscript; available in PMC 2011 September 1.
Published in final edited form as: Anticancer Agents Med Chem. 2010 September 1; 10(7): 571–581.
PMCID:
PMC2980558
Abstract Full Text PDF–407K
Experimental approaches for the treatment of malignant gliomas
Leopold Arko, Igor Katsyv, Grace E. Park, William Patrick Luan, John K. Park
Pharmacol Ther. Author manuscript; available in PMC 2011 October 1.
Published in final edited form as: Pharmacol Ther. 2010 October; 128(1): 1–36. Published online 2010 June 8. doi: 10.1016/j.pharmthera.2010.04.015
PMCID:
PMC2939300
Abstract Full Text PDF–1.4M
Emerging anti-cancer therapeutic targets and the cardiovascular system: Is there cause for concern?
Xuyang Peng, Laura Pentassuglia, Douglas B. Sawyer
Circ Res. Author manuscript; available in PMC 2011 April 2.
Published in final edited form as: Circ Res. 2010 April 2; 106(6): 1022–1034. doi: 10.1161/CIRCRESAHA.109.211276
PMCID:
PMC2872548
Abstract Full Text PDF–749K
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2
Roni Mamluk, Irvith M Carvajal, Brent A Morse, Henry Wong, Janette Abramowitz, Sharon Aslanian, Ai-Ching Lim, Jochem Gokemeijer, Michael J Storek, Joonsoo Lee, Michael Gosselin, Martin C Wright, Ray T Camphausen, Jack Wang, Yan Chen, Kathy Miller, Kerry Sanders, Sarah Short, Jeff Sperinde, Gargi prasad, Stephen Williams, Robert Kerbel, John ebos, Anthony Mutsaers, John D Mendlein, Alan S Harris, Eric S Furfine
MAbs. 2010 Mar-Apr; 2(2): 199–208.
PMCID:
PMC2840239
Abstract Full Text PDF–1.3M Supplementary Material
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan, Shundong Cang, Yuehua Ma, Richard L Petrillo, Delong Liu
J Hematol Oncol. 2010; 3: 5. Published online 2010 February 4. doi: 10.1186/1756-8722-3-5
PMCID:
PMC2827364
Abstract Full Text PDF–398K
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
K S Peggs, S A Quezada, J P Allison
Clin Exp Immunol. 2009 July; 157(1): 9–19. doi: 10.1111/j.1365-2249.2009.03912.x
PMCID:
PMC2710587
Abstract Full Text PDF–275K
Monoclonal antibodies in the treatment of pancreatic cancer
Zhi-Qiang Huang, Donald J Buchsbaum
Immunotherapy. Author manuscript; available in PMC 2010 January 1.
Published in final edited form as: Immunotherapy. 2009 March 1; 1(2): 223–239. doi: 10.2217/1750743X.1.2.223
PMCID:
PMC2747759
Abstract Full Text PDF–677K
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
Sean P Dineen, Laura A Sullivan, Adam W Beck, Andrew F Miller, Juliet G Carbon, Roni Mamluk, Henry Wong, Rolf A Brekken
BMC Cancer. 2008; 8: 352. Published online 2008 November 27. doi: 10.1186/1471-2407-8-352
PMCID:
PMC2627916
Abstract Full Text PDF–2.7M
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk